Research programme: anti-cancer therapeutics - Proteros biostructures/Janssen

Drug Profile

Research programme: anti-cancer therapeutics - Proteros biostructures/Janssen

Alternative Names: Covalent Flt3-Cys828 inhibitors - Proteros biostructures; Fms like tyrosine kinase 3 inhibitors - Proteros biostructures

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteros Biostructures
  • Developer Janssen; Proteros Biostructures
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • Research Cancer

Most Recent Events

  • 27 Jul 2017 Proteros biostructures and Janssen Biotech enter into a research collaboration for developing cancer therapeutics against epigenetic targets
  • 03 Jun 2016 Preclinical trials in Acute myeloid leukaemia (Flt3 mutant) in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top